NEW YORK: Abcam has entered a global distribution agreement to sell Avacta's recently developed SARS-CoV-2 research ELISA Affimer reagents, Avacta said on Tuesday.
Under the non-exclusive distribution agreement, Cambridge, UK-based Abcam will sell Avacta’s SARS-CoV-2 spike protein Affimer research reagents.
The deal will enable scientists to perform ELISA laboratory tests to detect the SARS-CoV-2 spike protein and dominant variants such as B117, also known as the Kent strain, and D614G, Wetherby, UK-based Avacta said.
Financial and other terms of the agreement were not disclosed.